HIV感染孕妇异烟肼预防性治疗的不良妊娠结局:随机试验的个体与复合结局分析
IMPAACT P1078随机非劣效试验的二次分析纳入925对母婴,比较妊娠期与产后启动28周异烟肼预防性治疗(IPT)的安全性。调整已知风险因素后,妊娠期立即启动IPT与三种复合不良妊娠结局风险升高相关,但个体结局风险未显著升高。
要点
- 妊娠期启动IPT增加复合不良妊娠结局风险,调整后OR约1.6-1.7。
- 个体结局(如死胎、早产、低出生体重)风险未见显著升高。
- 所有母亲均接受抗逆转录病毒治疗,来自8个结核高负担国家。
核心结论
- 调整已知不良妊娠结局风险因素后,妊娠期启动IPT仍与复合不良妊娠结局风险升高相关。
研究设计与样本
- IMPAACT P1078随机非劣效试验的二次分析,纳入925对母婴。
- 孕妇来自8个结核发病率>60/100 000的国家,随机分为妊娠期启动IPT或产后12周启动IPT,疗程28周。
- 所有母亲均接受抗逆转录病毒治疗。
主要发现
- 复合结局1(死胎、早产、低出生体重或先天畸形)调整后OR为1.63(95%CI 1.15-2.31),立即IPT组高于延迟IPT组。
- 复合结局2(死胎、早产、低出生体重或新生儿28天内死亡)调整后OR为1.62(95%CI 1.14-2.30)。
- 复合结局3(7天内早期新生儿死亡、死胎、早产或低出生体重)调整后OR为1.74(95%CI 1.22-2.49)。
临床怎么用
- 对HIV感染孕妇启动IPT时,应权衡复合不良妊娠结局风险,考虑产后延迟启动。
- 需结合结核暴露风险和妊娠期安全评估个体化决策。
局限性
- 为二次分析,复合结局的个体组分风险未显著升高。
- 研究仅纳入结核高负担国家且所有母亲均接受抗逆转录病毒治疗,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes. Many known factors are associated with adverse pregnancy outcomes: these factors' associations and effect modifications with IPT and pregnancy outcomes were examined. METHODS: Pregnant women living with HIV from 8 countries with tuberculosis incidences >60/100 000 were randomly assigned to initiate 28 weeks of IPT either during pregnancy or at 12 weeks after delivery. Using univariable and multivariable logistic regression and adjusting for factors associated with pregnancy outcomes, composite and individual adverse pregnancy outcome measures were analyzed. RESULTS: This secondary analysis included 925 mother-infant pairs. All mothers were receiving antiretrovirals. The adjusted odds of fetal demise, preterm delivery (PTD), low birth weight (LBW), or a congenital anomaly (composite outcome 1) were 1.63 times higher among women on immediate compared to deferred IPT (95% confidence interval [CI], 1.15-2.31). The odds of fetal demise, PTD, LBW, or neonatal death within 28 days (composite outcome 2) were 1.62 times higher among women on immediate IPT (95% CI, 1.14-2.30). The odds of early neonatal death within 7 days, fetal demise, PTD, or LBW (composite outcome 3) were 1.74 times higher among women on immediate IPT (95% CI, 1.22-2.49). CONCLUSIONS: We confirmed higher risks of adverse pregnancy outcomes associated with the initiation of IPT during pregnancy, after adjusting for known risk factors for adverse pregnancy outcomes.
引用
- Theron G, Montepiedra G, Aaron L, et al. Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 32997744. doi:10.1093/cid/ciaa1482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。